Ther-Rx and Perrigo announced that Gynazole-1 (butaconazole nitrate) vaginal cream 2% is now available again. Gynazole-1 cream is indicated for the local treatment of vulvovaginal candidiasis ...

. hopes to make and market a generic version of yeast infection fighter Gynazole 1 vaginal cream by the end of this year. The maker of store-brand pharmaceuticals announced that it has received final ...

Good news flowed in at Perrigo Company (PRGO) when the U.S. Food and Drug Administration (:FDA) cleared its generic version of KV Pharmaceutical Company’s vaginal cream Gynazole·1. Final approval was ...

Allegan-based Perrigo Co. (Nasdaq: PRGO) Friday announced that it has filed with the United States Food and Drug Administration an Abbreviated New Drug Application for butoconazole nitrate vaginal ...

Perrigo announced that it has received final approval from the FDA for Butoconazole nitrate 2% vaginal cream, the generic equivalent of Ther-Rx‘s Gynazole-1 vaginal cream. Butoconazole nitrate, an ...

ALLEGAN -- Perrigo Co. (Nasdaq: PRGO) announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated new drug application for butoconazole nitrate 2% ...

ST. LOUIS — Perrigo and a subsidiary of K-V Pharmaceutical Co. have launched a new drug for yeast infections in women, the two companies said. Perrigo and Ther-Rx Corp. announced the availability of ...

Aug. 29, 2005 — Health Canada has reinstated marketing authorization for a once-daily, extended-release formulation of a single-entity amphetamine product used to treat attention deficit/hyperactivity ...

KV Pharmaceutical Co. will sell its Gynazole-1 treatment in the People's Republic of China through an agreement signed with HuGang New Asiatic, the company said Monday. HuGang New Asiatic, a division ...